Uganda

uganda country outline

Estimated Number of Current PrEP Users

4,000-5,000

Aggregate Target Number of PrEP Users from All Projects (Planned and Ongoing)

23,000-23,500

PEPFAR Target in COP 2017

11,757

Types of Delivery Projects

  • Clinical trial
  • Demonstration projects
  • Implementation initiative
  • Large-scale implementation initiative
  • National level

*Definitions of types of projects available in the glossary below.

Drug Registration Status

  • Gilead’s Truvada (TDF/FTC) registeration is planned and in progress
  • Generic versions of TDF/FTC are approved for prevention

Research, Demonstration and Implementation Projects

Click here for a full list of ongoing and planned research/demonstration projects in Uganda.

Policy Framework

Funding

NIMH, USAID, The Bill & Melinda Gates Foundation, PEPFAR, NIH, IMPAACT Network, Uganda Ministry of Health, Nike Foundation


Eligibility Criteria
Resources for Uganda
Glossary of Terms

Last updated April 16, 2018.

News Spotlight

  • FDA Approves Truvada as PrEP for Adolescents at Risk for HIV

    May 15, 2018

    The US Food and Drug Administration has expanded the approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV to include adolescents. Truvada was approved as an HIV prevention method in 2012 but only for individuals age 18 and older. The new approval expands this indication to include adults and adolescents at risk for HIV.

    Read more

  • Early PrEP Uptake in Africa Study Gives Support for Possibility of Wider Acceptance

    May 9, 2018

    New findings show that nearly a fifth of adults whose risk for HIV infection made them eligible for free PrEP started taking the drug within 30 days — according to a study examining the impacts of health interventions across communities in two East African countries. The study’s authors conclude that this provides further evidence that widespread roll out of PrEP to individuals at high risks for infection across resource-limited communities is feasible.

    Read more